Virbac stock rises 2.31 percent as H1 margins expand

Published on 09/28/2026 at 12:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac stock trades at EUR 310.50 on September 28, 2026, after H1 revenue reached EUR 768.0 million. Adjusted EBIT rose to EUR 144.2 million as Bernstein lifted its target.

Schwarzweißes Reportagefoto eines Veterinärlabors mit Forschern bei der Arbeit — Dokumentarische Schwarzweiß-Reportage über Virbac S.A., Aktie FR0000031577, zeigt ein modernes Labor der Tiergesundheitsbranche, Illustration mit AI erstellt.

Virbac stock (ISIN FR0000031577) was trading at EUR 310.50 on Euronext Paris on September 28, 2026, up 2.31 percent from the prior close of EUR 303.50. The move follows first-half results that showed EUR 768.0 million in revenue and a 7.4 percent increase at constant exchange rates and scope, according to Virbac on September 17, 2026.

Margins strengthen in H1 2026

Virbac reported adjusted EBIT of EUR 144.2 million for H1 2026, compared with EUR 135.0 million in H1 2025. That represents growth of 6.8 percent, while the adjusted EBIT margin reached 18.8 percent versus 18.3 percent a year earlier, according to Reuters on September 17, 2026.

The revenue mix was led by companion animal products, which grew 10.0 percent, while farm animal revenue increased 6.7 percent. Virbac also reported net income of EUR 87.1 million for the half year, an increase of 5.9 percent from H1 2025, according to Virbac.

Guidance stays at the upper end

Management confirmed its 2026 revenue-growth range of 5.5 percent to 7.5 percent at constant rates and scope. The first-half performance gives the company a basis for targeting the upper end of that range, while the adjusted recurring operating income margin target remains 17 percent, according to Reuters.

The main operating question is whether the stronger first-half margin can carry into the second half. Virbac said higher operating expenses and normal period phasing affected the first six months, while its Supercharge platforms grew 12 percent excluding Thyronorm, according to Virbac.

Bernstein raises its target

Bernstein upgraded Virbac to Outperform from Market Perform and raised its price target from EUR 419.00 to EUR 426.00 on September 21, 2026. The new target lies 37.20 percent above the EUR 310.50 share price, while the analyst cited margin expansion from the Supercharge portfolio, as reported by Investing.com.

Virbac stock reaches EUR 310.50

Virbac stock was last at EUR 310.50 on Euronext Paris on September 28, 2026 at 11:46 a.m. CEST, with a session range of EUR 305.50 to EUR 310.50. Its market capitalization was EUR 2.6 billion and its 52-week range was EUR 297.00 to EUR 389.50.